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MUC1 glycoprotein is produced by normal breast epithe-
lial cells and cyclin B1 is involved in the transition from
G2-to-M phase of the normal cell cycle. In cancer cells,
including breast cancer, MUC1 and cyclin B1 are overex-
pressed and aberrantly expressed leading to their recogni-
tion by the immune system and production of specific
antibodies detected in the serum of cancer patients.
Because MUC1 and cyclin B1 are expected to be deregu-
lated early in disease, we hypothesized that monitoring
these antibody responses may be of diagnostic or prog-
nostic value in breast cancer (BC). Furthermore, we
wanted to test if NAF can be an alternative source of these
antibodies.
Objective/hypothesis
The hypothesis is that NAF would contain anti MUC1 and
anti-cyclin B1 antibodies in patients with BC and prema-
lignant lesions in comparison with healthy women.
Aim
The aim of this project was to test NAF for the presence of
anti-MUC1 and anti cyclin B1 antibody in patients with
BC, premalignant lesions and healthy women.
Materials and methods
We collected the pretreatment NAF of patients with BC,
non invasie tumor, premalignant lesions (atypical ductal-
, and lobular hyperplasia), and also healthy women. Anti
MUC1 and anti cyclin B1 antibody levels were measured
by an enzyme linked immunosorbent assay (ELISA). NAF
samples were taken from breasts with disease and the con-
tralateral healthy breast, and breasts of healthy women
operated upon for benign breast diseases. The mean level
of the antibody levels of patients and healthy controls in
NAF were compared by a t-test. The discrimination of the
antibody levels of patients and healthy controls in NAF
were assessed by calculating the area under (AUC) the
receiver operating characteristic curve (ROC).
Results
A total 82 NAF samples from 50 patients were collected;
35 NAF samples were collected from breasts with invasive
cancer, 12 samples with ADH and ALH, 5 samples with
DCIS and LCIS, 2 samples with benign lesions and 28
samples from healthy breasts. There were no statistically
significant difference between the invasive tumor, high-
risk lesion and control groups, but AUC under the ROC
was 0.78 and 0.69 in anti MUC1 and anti Cyclin B1 IgM
groups between non-invasive tumor group and controls;
it is generally accepted that AUC values 0.7–0.8 represent
good discrimination.
Conclusion
This is the first study investigating anti-MUC1 and anti
cyclin B1 antibodies in NAF of BC patients. Even though
the sample size is still small and additional samples are
being accumulated, finding the tumor specific IgM in the
NAF of the non invasive patients is encouraging. Develop-
ment of more sensitive techniques for antibody detection
may allow detection of low antibody levels in the non
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invasive tumor and premalignant lesions and boost the
usefulness of NAF as the source for this diagnostic assay.
Combining NAF biomarkers with clinical parameters such
as breast density and scoring systems for the clinical judg-
ment of breast tumors may be clarified by future studies.